[ad_1]
Chief Researcher of the Life Sciences Center of Vilnius University prof. Aurelija Žvirblienė Delfi stated that during the meeting data were presented from several studies conducted in other countries, when immunosuppressed patients are revaccinated with the third dose.
“These are cases where a person simply does not develop antibodies after a full vaccination cycle, or there are very few of them. The results of such studies were presented. The third dose increases the level of antibodies considerably for some,” he said. A. Žvirblienė.
According to the professor, it is considered that also in Lithuania it should be proposed to initiate revaccination of immunosuppressed patients who are subject to immunosuppression for health reasons. Your immune response is ineffective. It is also ineffective in the vaccine.
“It just came to our knowledge then. Usually there are no specific decisions in the meetings of the Board of Experts. The representatives of the Ministry of Health listened to the data of the scientists and then they will make decisions,” said A. Žvirblienė.
We are talking about very small groups in society.
According to the professor, immunosuppressed people refer to people who have received an organ transplant and are on immunosuppressive treatment.
“It just came to our knowledge then. This is a maximum of a few thousand (patients), or maybe not. It is definitely not hundreds or tens of thousands of people,” said A. Žvirblienė.
Oncological immunologist from the National Cancer Institute (IMI) dr. Marius Strioga added that in addition to immunosuppressed people, there are also patients with autoimmune and blood cancer diseases.
The researcher emphasized that not all cancer patients are referred here and are being treated with chemotherapy.
“That’s to be expected, but not at this stage,” Strioga said.
The IMI researcher believes that the revaccination process of these immunosuppressed individuals will soon begin. According to him, further ahead are the grandparents of nursing homes, whose revaccination could also begin in the near future.
I look forward to the data from the manufacturers.
According to the professor, there are no plans yet to start revaccination for the general public. The interviewee said that the question of whether it would still be necessary to vaccinate the general public that has been vaccinated since spring during the summer this cold season of the year remains open.
“It just came to our attention then. It depends on the age of the person. Personally, I would like to receive specific data from vaccine manufacturers. They have longer-term data,” said A. Žvirblienė.
Medical vaccination is still under discussion.
“It just came to our attention at the time, but there was a general consensus that there was no particular urgency. It is also necessary to wait for the practice of other countries ”, said A. Žvirblienė.
The professor noted that the UK has already announced that it will start booster shots from September. Israel has already started this process from certain priority groups.
“This is being done gradually,” said A. Žvirblienė.
Strioga thinks the booster shot (of his choice) could start in September, maybe October.
Scientific data was presented on the possibility of sharing vaccines.
The experts presented scientific data on the possibility of mixing vaccines. That is, if a vaccine was given for the first time, allow a booster shot with another type of vaccine.
The position of scientists on this issue is very positive.
“I presented data from three studies conducted in Germany, the UK and Spain. Scientific data shows that alternating different vaccines is effective, antibodies increase and cellular response is good, ”said A. Žvirblienė.
According to the professor, the data on adverse reactions differ slightly.
“There is evidence from some countries that the reactogenicity is just lower. But, for example, there is data from the UK that after the Vaxzevria vaccine, Commirnaty was injected or vice versa, that the reactogenicity was higher than if we compared the same doses of vaccines. ”Said A. Žvirblienė.
However, according to the professor, this remains a debatable topic.
“Some countries had the same dose interval, like four weeks, while others, like Germany, used a longer interval for different vaccines. That’s eight to twelve weeks, and then that reactogenicity data is better. That is, if there is a longer interval between doses, then there are fewer adverse reactions, ”said A. Žvirblienė.
The professor pointed out that so far there are no official recommendations from manufacturers or agencies on how to alternate vaccines on these issues.
“But some countries use this practice because, for example, they no longer use the Vaxzevria vaccine. So you either want or don’t want to use a vaccine from another manufacturer,” said A. Žvirblienė.
It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to cite DELFI as the source. .
[ad_2]
